MRI contrast agents: Basic chemistry and safety

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 5, 2012, Pages 1060-1071

  Hao, Dapeng ^a   Ai, Tao ^b   Goerner, Frank ^c   Hu, Xuemei ^b   Runge, Val M ^c   Tweedle, Michael ^d  

^a QINGDAO UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c University of Texas Medical Branch School of Medicine   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

adverse reaction; contrast agent; gadolinium; MRI; nephrogenic systemic fibrosis; stability

Indexed keywords

CHELATE; CONTRAST MEDIUM; GADOLINIUM;

CHEMISTRY; DRUG SAFETY; DRUG STABILITY; HUMAN; HYPOCALCEMIA; IN VIVO STUDY; KINETICS; MOLECULAR IMAGING; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOLALITY; PRIORITY JOURNAL; REVIEW; TASTE DISORDER; THERMODYNAMICS; URTICARIA; VISCOSITY;

CONTRAST MEDIA; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING;

EID: 84867760239     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23725     Document Type: Review

References (75)

1. Weinmann HJ, Brasch RC, Press WR, Wesbey GE,. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984; 142: 619-624.
2. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB,. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999; 99: 2293-2352.
3. Lauffer RB, Brady TJ,. Preparation and water relaxation properties of proteins labeled with paramagnetic metal chelates. Magn Reson Imaging 1985; 3: 11-16.
4. Tweedle MF, Eaton SM, Eckelman WC, et al. Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 1988; 23 (Suppl): 236-239.
5. Bonnemain B, Meyer D,. Present aspects of MRI contrast agents - early experience with DOTA gadolinium. In: "MR 85" Meeting. Garmisch Partenkirchen, West Germany; January 24-27, 1985. p 81-88.
6. Runge VM,. Clinical MRI. Philadelphia: Saunders; 2002. p 454-457.
7. Maiocchi A,. The use of molecular descriptors in the design of gadolinium (III) chelates as MRI contrast agents. Mini Rev Med Chem 2003; 3: 845-859.
8. Strijkers GJ, Mulder WJ, van Tilborg GA, Nicolay K,. MRI contrast agents: current status and future perspectives. Anticancer Agents Med Chem 2007; 7: 291-305.
9. Gibby WA, Gibby KA,. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004; 39: 138-142.
10. Schmitt-Willich H,. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007; 80: 583-584; author reply 584-585.
11. Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C,. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008; 21: 469-490.
12. Wedeking P, Kumar K, Tweedle MF,. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992; 10: 641-648.
13. Major JL, Meade TJ,. Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res 2009; 42: 893-903.
14. Carrier DA, Ford JJ, Hayman LA,. MR appearance of extravasated gadolinium contrast medium. AJNR Am J Neuroradiol 1993; 14: 363-364.
15. Runge VM, Dickey KM, Williams NM, Peng X,. Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. Invest Radiol 2002; 37: 393-398.
16. Runge VM, Price AC, Wehr CJ, Atkinson JB, Tweedle MF,. Contrast enhanced MRI. Evaluation of a canine model of osmotic blood-brain barrier disruption. Invest Radiol 1985; 20: 830-844.
17. Tweedle MF,. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992; 27 (Suppl): 2-6.
18. Runge VM,. Enhanced magnetic resonance imaging. St. Louis: Mosby; 1989. p 57-63.
19. Tweedle MF,. The ProHance story: the making of a novel MRI contrast agent. Eur Radiol 1997; 7 (Suppl): 225-230.
20. Raymond KN, Pierre VC,. Next generation, high relaxivity gadolinium MRI agents. Bioconjug Chem 2005; 16: 3-8.
21. Chang CA BH, Telser J, Tweedle MF,. pH dependence of relaxivities and hydration numbers of gadolinium(III) complexes of linear amino carboxylates. Inorg Chem 1990; 29: 4468-4473.
22. Zhang X, Chang CA, Brittain HG, MF T,. pH dependence of relaxivities and hydration numbers of gadolinium(III) complexes of macrocyclic amino carboxylates. Inorg Chem 1992; 31: 5597-5600.
23. Aime S, Botta M, Terreno E, Anelli PL, Uggeri F,. Gd(DOTP)5-outer-sphere relaxation enhancement promoted by nitrogen bases. Magn Reson Med 1993; 30: 583-591.
24. 3+ complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities. Inorg Chem 2001; 40: 6580-6587.
25. Runge VM,. Contrast media in magnetic resonance imaging: a clinical approach. Philadelphia: Lippincott: 1992.
26. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ,. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol 2008; 43: 817-828.
27. Schmitt-Willich H, Brehm M, Ewers CL, et al. Synthesis and physicochemical characterization of a new gadolinium chelate: the liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA. Inorg Chem 1999; 38: 1134-1144.
28. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ,. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724.
29. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41: 213-221; erratum 859.
30. Cacheris WP, Quay SC, Rocklage SM,. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990; 8: 467-481.
31. Cram DJ,. The design of molecular hosts, guests, and their complexes. Science 1988; 240: 760-767.
32. 3+ complexes of macrocyclic polyamino carboxylates. Inorg Chem 1994; 33: 3823-3829.
33. Laurent S, Elst LV, Muller RN,. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006; 1: 128-137.
34. Tweedle MF, Gaughan GT, Hagan J, et al. Considerations involving paramagnetic coordination compounds as useful NMR contrast agents. Int J Rad Appl Instrum B 1988; 15: 31-36.
35. Tweedle MF, Hagan JJ, Kumar K, Mantha S, Chang CA,. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991; 9: 409-415.
36. Idee JM, Port M, Dencausse A, Lancelot E, Corot C,. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009; 47: 855-869.
37. Wedeking P, Sotak CH, Telser J, Kumar K, Chang CA, Tweedle MF,. Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat. Magn Reson Imaging 1992; 10: 97-108.
38. Rofsky NM, Sherry AD, Lenkinski RE,. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 2008; 247: 608-612.
39. Tweedle MF, Wedeking P, Kumar K,. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995; 30: 372-380.
40. Idee JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008; 248: 77-88.
41. White GW, Gibby WA, Tweedle MF,. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41: 272-278.
42. Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998; 207: 529-538.
43. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H,. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991; 22: 233-237; discussion 242.
44. Ersoy H, Rybicki FJ,. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007; 26: 1190-1197.
45. Lin SP, Brown JJ,. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 2007; 25: 884-899.
46. Morcos SK,. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008; 66: 175-179.
47. Bousquet JC, Saini S, Stark DD, et al. Gd-DOTA: characterization of a new paramagnetic complex. Radiology 1988; 166: 693-698.
48. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ,. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008; 43: 65-75.
49. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008; 27: 955-962.
50. Corot C, Idee JM, Hentsch AM, et al. Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. J Magn Reson Imaging 1998; 8: 695-702.
51. Laurent S, Elst LV, Copoix F, Muller RN,. Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol 2001; 36: 115-122.
52. Idee JM, Berthommier C, Goulas V, et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals 1998; 11: 113-123.
53. Emerson J, Kost G,. Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value. Arch Pathol Lab Med 2004; 128: 1151-1156.
54. Normann PT, Froysa A, Svaland M,. Interference of gadodiamide injection (Omniscan) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest 1995; 55: 421-426.
55. Wible JH Jr, Hynes MR,. Measurement of serum calcium concentration after administration of gadoversetamide in dogs. Radiology 2004; 233: 158-164.
56. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003; 227: 639-646.
57. Runge VM,. Allergic reactions to gadolinium chelates. AJR Am J Roentgenol 2001; 177: 944-945.
58. Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP,. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006; 41: 491-499.
59. Maurer M, Heine O, Wolf M, Durmus T, Wagner M, Hamm B,. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol 2012; 81: 885-890.
60. Herborn CU, Honold E, Wolf M, et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 2007; 42: 58-62.
61. Bleicher AG, Kanal E,. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008; 191: 307-311.
62. Abujudeh HH, Kosaraju VK, Kaewlai R,. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol 2010; 194: 430-434.
63. Prince MR, Zhang H, Zou Z, Staron RB, Brill PW,. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011; 196: 138-143.
64. Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN,. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. Radiology 2011; 259: 109-116.
65. Lasser EC,. X-ray contrast media mechanisms in the release of mast cell contents: understanding these leads to a treatment for allergies. J Allergy (Cairo) 2011; 2011: 276258.
66. Thomsen HS,. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006; 16: 2619-2621.
67. Elmholdt TR, Pedersen M, Jorgensen B, et al. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. Br J Dermatol 2011; 165: 828-836.
68. Cowper SE, Rabach M, Girardi M,. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; 66: 191-199.
69. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157.
70. Swaminathan S, Shah SV,. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007; 18: 2636-2643.
71. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009; 44: 226-233.
72. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248: 799-806.
73. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007; 188: 1447-1474.
74. Penfield JG, Reilly RF Jr,. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 2007; 3: 654-668.
75. Runge VM,. Gadolinium and nephrogenic systemic fibrosis. AJR Am J Roentgenol 2009; 192: 195-196; discussion 197.